<DOC>
	<DOCNO>NCT01373060</DOCNO>
	<brief_summary>This study assess safety , tolerability , pharmacokinetics pharmacodynamics ASP1941 orally administer single dos healthy adult male Taiwanese subject .</brief_summary>
	<brief_title>A Study Assess Safety , Pharmacokinetics Pharmacodynamics ASP1941 Healthy Male Taiwanese Subjects</brief_title>
	<detailed_description>The subject administer single dose ASP1941 placebo fast condition . Plasma urine level ASP1941 glucose measure investigate pharmacokinetic pharmacodynamic property ASP1941 .</detailed_description>
	<criteria>Body weight 50 85 kg , Body Mass Index ( BMI ) 17.6 26.4 kg/m2 inclusive Medical history metabolic disease , hepatic disease , heart disorder , respiratory disease , gastrointestinal disease , renal disease , cerebrovascular disorder , malignant tumor , drug allergy drug/alcohol dependence Blood pressure , pulse rate , body temperature 12lead ECG outside preset normal range Labo test result deviate preset normal range Receiving treatment , include medication , within 14 day study Receiving medication another clinical study postmarketing clinical trial within 3 month study Donates 500mL whole blood within 3 month 250mL within 2 month blood component within 14 day study Drinking 45g alcohol , smoke 20 cigarette per day Employed sponsor , delegate CRO study site Fasting plasma glucose level &lt; 70 mg/dL ≥110 mg/dL HbA1c ≥5.8 % Subjects positive serology test Hepatitis B antigen , Hepatitis A virus IgM , antiHepatitis C virus antiHuman Immunodeficiency virus1 2</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>ASP1941</keyword>
	<keyword>ipragliflozin</keyword>
	<keyword>plasma glucose</keyword>
	<keyword>urine glucose</keyword>
</DOC>